MedTrace Logo

AR-12286 in Combination With Latanoprost

NCT01302249 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2014-05-08

No results posted yet for this study

Summary

This is a double-masked, randomized, multi-center, active-controlled, crossover comparison of the addition of AR-12286 or timolol to latanoprost in the treatment of elevated intraocular pressure (IOP).

Conditions

Interventions

DRUG

Latanoprost 0.005%

q.d.

DRUG

AR-12286 Ophthalmic Solution 0.5%

DRUG

Timolol maleate ophthalmic solution 0.5%

Sponsors & Collaborators

  • Aerie Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01302249 on ClinicalTrials.gov